CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro

Gynecologic Oncology

Volumn 129, Issue 1, 2013, Pages 179-187

  Paatero, Ilkka ^a,b   Lassus, Heini ^c   Junttila, Teemu T ^a,b   Kaskinen, Matti ^a   Bützow, Ralf ^c   Elenius, Klaus ^a,d  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

ErbB4; Growth factors; HER4; Ovarian cancer; Signal transduction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 4;

ADULT; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

ADULT; AGED; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE ARRAY ANALYSIS;

EID: 84875460315     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.12.044     Document Type: Article

References (33)

1. R.J. Bast, B. Hennessy, and G. Mills The biology of ovarian cancer: new opportunities for translation Nat Rev Cancer 9 2009 415 428
2. S. Vaughan, J.I. Coward, R.C. Bast Jr., A. Berchuck, J.S. Berek, and J.D. Brenton Rethinking ovarian cancer: recommendations for improving outcomes Nat Rev Cancer 11 2011 719 725
3. A.P. Heintz, F. Odicino, P. Maisonneuve, M.A. Quinn, J.L. Benedet, and W.T. Creasman Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer Int J Gynaecol Obstet 95 Suppl. 1 2006 S161 S192
4. Y. Yarden, and G. Pines The ERBB network: at last, cancer therapy meets systems biology Nat Rev Cancer 12 2012 553 563
5. N. Hynes, and H. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 2005 341 354
6. H. Lassus, H. Sihto, A. Leminen, H. Joensuu, J. Isola, and N. Nupponen Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma J Mol Med 84 2006 671 681
7. L. Gilmour, K. Macleod, A. McCaig, W. Gullick, J. Smyth, and S. Langdon Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer Cancer Res 61 2001 2169 2176
8. K. Steffensen, M. Waldstrøm, R. Andersen, D. Olsen, U. Jeppesen, and H. Knudsen Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors Int J Oncol 33 2008 195 204
9. T. Pejovic, N. Pande, M. Mori, P. Mhawech-Fauceglia, C. Harrington, and S. Mongoue-Tchokote Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes Transl Oncol 2 2009 341 349
10. M. Campiglio, S. Ali, P. Knyazev, and A. Ullrich Characteristics of EGFR family-mediated HRG signals in human ovarian cancer J Cell Biochem 73 1999 522 532
11. L. Gilmour, K. Macleod, A. McCaig, J. Sewell, W. Gullick, and J. Smyth Neuregulin expression, function, and signaling in human ovarian cancer cells Clin Cancer Res 8 2002 3933 3942
12. V. Veikkolainen, K. Vaparanta, K. Halkilahti, K. Iljin, M. Sundvall, and K. Elenius Function of ERBB4 is determined by alternative splicing Cell Cycle 10 2011 2647 2657
13. K. Elenius, C. Choi, S. Paul, E. Santiestevan, E. Nishi, and M. Klagsbrun Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase Oncogene 18 1999 2607 2615
14. V. Kainulainen, M. Sundvall, J. Määttä, E. Santiestevan, M. Klagsbrun, and K. Elenius A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis J Biol Chem 275 2000 8641 8649
15. R. Muraoka-Cook, M. Sandahl, K. Strunk, L. Miraglia, C. Husted, and D. Hunter ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo Mol Cell Biol 29 2009 4935 4948
16. E. Ferretti, L. Di Marcotullio, M. Gessi, T. Mattei, A. Greco, and A. Po Alternative splicing of the ErbB-4 cytoplasmic domain and its regulation by hedgehog signaling identify distinct medulloblastoma subsets Oncogene 25 2006 7267 7273
17. H. Lassus, A. Leminen, J. Lundin, P. Lehtovirta, and R. Butzow Distinct subtypes of serous ovarian carcinoma identified by p53 determination Gynecol Oncol 91 2003 504 512
18. T. Junttila, M. Laato, T. Vahlberg, K. Söderström, T. Visakorpi, and J. Isola Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients Clin Cancer Res 9 2003 5346 5357
19. H. Lassus, A. Leminen, A. Vayrynen, G. Cheng, J.A. Gustafsson, and J. Isola ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma Gynecol Oncol 92 2004 31 39
20. T.C. Hamilton, R.C. Young, W.M. McKoy, K.R. Grotzinger, J.A. Green, and E.W. Chu Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors Cancer Res 43 1983 5379 5389
21. J. Fogh, J.M. Fogh, and T. Orfeo One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice J Natl Cancer Inst 59 1977 221 226
22. D. Tvorogov, M. Sundvall, K. Kurppa, M. Hollmén, S. Repo, and M. Johnson Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer J Biol Chem 284 2009 5582 5591
23. Y. Benjamini, and Y. Hochberg Controlling the false discovery rate - a practical and powerful approach to multiple testing J Roy Statist Soc Ser B 57 1995 289 300
24. T. Junttila, M. Sundvall, M. Lundin, J. Lundin, M. Tanner, and P. Härkönen Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells Cancer Res 65 2005 1384 1393
25. M.N. Bijman, M.P. van Berkel, M. Kok, M.L. Janmaat, and E. Boven Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines Anticancer Drugs 20 2009 450 460
26. M. Sundvall, A. Korhonen, I. Paatero, E. Gaudio, G. Melino, and C. Croce Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms Proc Natl Acad Sci U S A 105 2008 4162 4167
27. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 2009 550 562
28. C. Ni, M. Murphy, T. Golde, and G. Carpenter gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase Science 294 2001 2179 2181
29. J. Määttä, M. Sundvall, T. Junttila, L. Peri, V. Laine, and J. Isola Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth Mol Biol Cell 17 2006 67 79
30. M. Gordon, D. Matei, C. Aghajanian, U. Matulonis, M. Brewer, and G. Fleming Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status J Clin Oncol 24 2006 4324 4332
31. M. Palayekar, and T. Herzog The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer Int J Gynecol Cancer 18 2008 879 890
32. S. Makhija, L. Amler, D. Glenn, F. Ueland, M. Gold, and D. Dizon Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer J Clin Oncol 28 2010 1215 1223
33. C.G.A.R. Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615